GlassScriptPhysician profile
Nina Bhatia
NPI 1295960706
$76,802.29
in general payments reported to CMS, 2019-2025
26 companies · $808 in 2025
The $808 reported for 2025 was more than what a typical Urogynecology and Reconstructive Pelvic Surgery (Obstetrics & Gynecology) provider received nationally (typical 2025 total: $413).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $17K · 2020: $2,729 · 2021: $1,676 · 2022: $27K · 2023: $19K · 2024: $8,376 · 2025: $808.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $19K · Food and Beverage: $4,817 · Travel and Lodging: $4,405 · Honoraria: $241 · Education: $54.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $18,780.51 |
| Food and Beverage | $4,816.59 |
| Travel and Lodging | $4,404.83 |
| Honoraria | $241.16 |
| Education | $54.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coloplast Corp | $53,962.25 | 2019-2025 | Altis, Restorelle, Saffron |
| Intuitive Surgical, INC. | $12,740.43 | 2019-2023 | Da Vinci Surgical System |
| Axonics, INC. | $4,102.82 | 2020-2024 | Axonics, Bulkamid |
| Caldera Medical, INC | $2,224.58 | 2019-2023 | Desara |
| Seaspine Orthopedics Corporation | $806.87 | 2019 | |
| Medtronic, INC. | $783.54 | 2021-2025 | Endoflip, Interstim |
| Boston Scientific Corporation | $776.00 | 2019-2025 | Axonics, Upsylon, Solyx Sis System |
| Momentis Surgical INC. | $183.00 | 2022 | |
| Allergan, INC. | $174.07 | 2019-2022 | |
| Medtronic USA, INC. | $148.10 | 2019-2020 | |
| Abbvie INC. | $144.16 | 2019-2024 | Botox |
| Pfizer INC. | $131.52 | 2019-2022 | |
| Astellas Pharma US INC | $127.41 | 2019-2022 | |
| Therapeuticsmd, INC. | $95.04 | 2019 | |
| Sumitomo Pharma America, INC. | $87.04 | 2023-2025 | Gemtesa |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amag Pharmaceuticals, INC. | $80.88 | 2019 | |
| Bluewind Medical | $65.47 | 2024-2025 | |
| Avanos Medical | $44.61 | 2019 | |
| Contura, INC. | $29.86 | 2020 | |
| Biocompatibles, INC. | $16.34 | 2019 | |
| Millicent US INC | $15.26 | 2025 | Intrarosa |
| Mission Pharmacal Company | $14.98 | 2024 | Uribel Tabs |
| Avadel Specialty Pharmaceuticals, LLC | $14.82 | 2019 | |
| Mycovia Pharmaceuticals, INC. | $13.41 | 2023 | Vivjoa |
| Urovant Sciences INC | $12.33 | 2021 | |
| Escala Medical INC. | $7.50 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nina Bhatia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.